Xero faces A$80 test after AI bounce and holiday pause

Xero faces A$80 test after AI bounce and holiday pause

June 8, 2026

Sydney, June 9, 2026, 07:06 AEST

  • Xero closed at A$79.27 on June 5, off 1.41% for the session, though still ahead of where it finished the previous Friday.
  • The ASX cash market didn’t open on Monday because of the King’s Birthday holiday, so the market’s last traded levels from Friday were the reference point.
  • Xero’s U.S. push, its Melio integration and AI spending are in focus again after shares saw a sharp reset this year.

Xero Ltd comes into Tuesday’s ASX open at A$79.27, matching its close from Friday before the holiday break paused trading. The software company slipped 1.41% that day, though shares held above last week’s A$75.17 after rallying early and then seeing some sellers move in ahead of the long weekend.

Xero surged 7.69% on June 1 and another 7.47% on June 2 before pulling back over the next three sessions. The action left traders with no new local price since Friday, as the move failed to hold gains cleanly heading into Tuesday’s open.

Tech and chip stocks drove a Wall Street bounce Monday after Friday’s steep drop. The Philadelphia Semiconductor Index surged 6.2% and the S&P 500 technology sector added 1.8%, according to Reuters. The overnight lead turned less negative than late last week.

Australian shares dropped before the midweek break. The S&P/ASX 200 ended June 5 at 8,625.10, off 0.70% on the day and under its May 29 finish of 8,731.70. Xero’s rise for the week stood out as the main index lagged. The S&P/ASX 200 tracks 200 top ASX-listed stocks.

Xero sticks to the same story since May—growth with a price. The company posted a 31% jump in FY26 operating revenue to NZ$2.75 billion, while adjusted EBITDA rose 18% to NZ$757.4 million. Adjusted EBITDA takes out interest, tax, depreciation, amortisation and some one-offs. Net profit dropped 27% to NZ$167.4 million. The board green-lit up to A$550 million in share buybacks to balance out dilution from staff shares. CEO Sukhinder Singh Cassidy called it “disciplined execution and macro-resilience,” and said Xero is a “long-term AI winner.” Brandfolder

Xero is guiding for FY27 operating revenue between NZ$3.62 billion and NZ$3.73 billion, with adjusted EBITDA targeted at NZ$860 million to NZ$920 million. That forecast bakes in as much as NZ$55 million in extra U.S. brand spend, so investors are still watching if Xero can grow its U.S. business and hold margins.

Not every analyst focused on the same numbers. Citi’s Siraj Ahmed said Xero’s adjusted earnings beat consensus by 2%, but net profit came in light on higher interest and tax, Capital Brief reported. Despite that, Ahmed called the quarter “strong,” pointing to “US momentum,” better subscriber growth, and Melio outpacing forecasts. Capital Brief

US competition is the key issue for Xero as it tries to go after Intuit’s QuickBooks users. Last year, Reuters said Xero’s deal with Melio would bring payments to its accounting tools and help build up its US business, which accounted for around 7% of group sales at the time. RBC Capital Markets analyst Garry Sherriff saw “much to like” in growing the US push but warned it would take time. Reuters

Melio is telling customers who use competitor software that it will still support QuickBooks Online and QuickBooks Desktop. In its FAQ, Melio says those users will keep getting support. Xero gets a U.S. payments foothold from the acquisition, but it doesn’t guarantee a direct route to U.S. small businesses.

The downside case isn’t hard to see. If tech loses steam or Melio keeps weighing on gross margins, investors could stop focusing on revenue growth and start paying attention to what Xero shelled out for its U.S. push. Josh Gilbert, lead analyst at eToro, told The Australian that absorbing Melio’s lower-margin payments business was just “the cost of buying real scale in the US.” But he said investors may be asking how long the margin hit sticks around. The Australian

Xero doesn’t have a near-term scheduled event, with its annual meeting set for Aug. 27 and half-year results due Nov. 12, according to its investor calendar. That leaves Tuesday’s reopening with little in the way of corporate news, so market demand for growth names is likely to take the lead.

Stocks are attempting to keep some rebound going after a weak Friday in the broader market. One name is trying to convince investors to ignore the integration costs and focus on the bigger U.S. target. When trading starts up again after the holiday, the first trade will give a read on whether investors are sticking around or not.

Artur Ślesik

Artur Ślesik is a technology and financial markets journalist at Bez-kabli.pl, covering artificial intelligence, semiconductors, technology stocks and emerging innovations. A graduate of Warsaw University of Technology, he combines a technical background with market analysis to explain how new technologies are shaping industries, businesses and investment trends worldwide.

Stock Market Today

  • Oil tumbles as US pauses Iran action; AstraZeneca jumps on cancer drug sales
    July 27, 2026, 3:34 AM EDT. Oil dropped more than 5%-Brent crude fell 5.3% to $91.68-as the US held off new strikes on Iran after a round of internal debate. Iran stepped back from immediate retaliation too. Even with the pause, missile and drone threats near the Red Sea kept shippers wary and routes disrupted. European stocks rose on the oil drop, with the Stoxx Europe 600 gaining 0.9%, but UK energy names traded down. AstraZeneca posted an 18% gain in Q2 profit, fueled by higher cancer drug demand, and sales climbed 5% to $15.38 billion. BP lost 3.8% and Shell slid 2% as oil prices fell.